Top

Journal of Cardiovascular Translational Research

Published in:

Open Access 01-10-2013

Intramyocardial Injection of Autologous Bone Marrow-Derived Ex Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients is Feasible and Safe up to 5 Years of Follow-up

Authors: Sander F. Rodrigo, Jan van Ramshorst, Georgette E. Hoogslag, Helèn Boden, Matthijs A. Velders, Suzanne C. Cannegieter, Helene Roelofs, Imad Al Younis, Petra Dibbets-Schneider, Willem E. Fibbe, Jaap Jan Zwaginga, Jeroen J. Bax, Martin J. Schalij, Saskia L. Beeres, Douwe E. Atsma

Published in: Journal of Cardiovascular Translational Research | Issue 5/2013

Abstract

In experimental studies, mesenchymal stem cell (MSC) transplantation in acute myocardial infarction (AMI) models has been associated with enhanced neovascularization and myogenesis. Clinical data however, are scarce. Therefore, the present study evaluates the safety and feasibility of intramyocardial MSC injection in nine patients, shortly after AMI during short-term and 5-year follow-up. Periprocedural safety analysis demonstrated one transient ischemic attack. No other adverse events related to MSC treatment were observed during 5-year follow-up. Clinical events were compared to a nonrandomized control group comprising 45 matched controls. A 5-year event-free survival after MSC-treatment was comparable to controls (89 vs. 91 %, P = 0.87). Echocardiographic imaging for evaluation of left ventricular function demonstrated improvements up to 5 years after MSC treatment. These findings were not significantly different when compared to controls. The present safety and feasibility study suggest that intramyocardial injection of MSC in patients shortly after AMI is feasible and safe up to 5-year follow-up.

Jeevanantham, V., Butler, M., Saad, A., Abdel-Latif, A., Zuba-Surma, E. K., & Dawn, B. (2012). Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation, 126, 551–568.PubMedCrossRef

Silva, G. V., Litovsky, S., Assad, J. A., Sousa, A. L., Martin, B. J., Vela, D., Coulter, S. C., Lin, J., Ober, J., Vaughn, W. K., Branco, R. V., Oliveira, E. M., He, R., Geng, Y. J., Willerson, J. T., & Perin, E. C. (2005). Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation, 111, 150–156.PubMedCrossRef

Makino, S., Fukuda, K., Miyoshi, S., Konishi, F., Kodama, H., Pan, J., Sano, M., Takahashi, T., Hori, S., Abe, H., Hata, J., Umezawa, A., & Ogawa, S. (1999). Cardiomyocytes can be generated from marrow stromal cells in vitro. The Journal of Clinical Investigation, 103, 697–705.PubMedCrossRef

Dai, W., Hale, S. L., Martin, B. J., Kuang, J. Q., Dow, J. S., Wold, L. E., & Kloner, R. A. (2005). Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation, 112, 214–223.PubMedCrossRef

Chen, S. L., Fang, W. W., Ye, F., Liu, Y. H., Qian, J., Shan, S. J., Zhang, J. J., Chunhua, R. Z., Liao, L. M., Lin, S., & Sun, J. P. (2004). Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. The American Journal of Cardiology, 94, 92–95.PubMedCrossRef

Hare, J. M., Traverse, J. H., Henry, T. D., Dib, N., Strumpf, R. K., Schulman, S. P., Gerstenblith, G., DeMaria, A. N., Denktas, A. E., Gammon, R. S., Hermiller, J. B., Jr., Reisman, M. A., Schaer, G. L., & Sherman, W. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology, 54, 2277–2286.PubMedCrossRef

Williams, A. R., Trachtenberg, B., Velazquez, D. L., McNiece, I., Altman, P., Rouy, D., Mendizabal, A. M., Pattany, P. M., Lopera, G. A., Fishman, J., Zambrano, J. P., Heldman, A. W., & Hare, J. M. (2011). Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circulation Research, 108, 792–796.PubMedCrossRef

Vulliet, P. R., Greeley, M., Halloran, S. M., MacDonald, K. A., & Kittleson, M. D. (2004). Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet, 363, 783–784.PubMedCrossRef

Moelker, A. D., Baks, T., Wever, K. M., Spitskovsky, D., Wielopolski, P. A., van Beusekom, H. M., van Geuns, R. J., Wnendt, S., Duncker, D. J., & van der Giessen, W. J. (2007). Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. Journal of Molecular and Cellular Cardiology, 42, 735–745.PubMedCrossRef

10.

Hou, D., Youssef, E. A., Brinton, T. J., Zhang, P., Rogers, P., Price, E. T., Yeung, A. C., Johnstone, B. H., Yock, P. G., & March, K. L. (2005). Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation, 112, I150–I156.PubMed

11.

van Ramshorst, J., Bax, J. J., Beeres, S. L., Dibbets-Schneider, P., Roes, S. D., Stokkel, M. P., de Roos, A., Fibbe, W. E., Zwaginga, J. J., Boersma, E., Schalij, M. J., & Atsma, D. E. (2009). Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA : The Journal of the American Medical Association, 301, 1997–2004.CrossRef

12.

Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., Dini, G., Egeler, R. M., Bacigalupo, A., Fibbe, W., & Ringden, O. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371, 1579–1586.PubMedCrossRef

13.

Beeres, S. L., Bax, J. J., Dibbets, P., Stokkel, M. P., Zeppenfeld, K., Fibbe, W. E., van der Wall, E. E., Schalij, M. J., & Atsma, D. E. (2006). Effect of intramyocardial injection of autologous bone marrow-derived mononuclear cells on perfusion, function, and viability in patients with drug-refractory chronic ischemia. Journal of Nuclear Medicine, 47, 574–580.PubMed

14.

Mollema, S. A., Liem, S. S., Suffoletto, M. S., Bleeker, G. B., van der Hoeven, B. L., van de Veire, N. R., Boersma, E., Holman, E. R., van der Wall, E. E., Schalij, M. J., Gorcsan, J., III, & Bax, J. J. (2007). Left ventricular dyssynchrony acutely after myocardial infarction predicts left ventricular remodeling. Journal of the American College of Cardiology, 50, 1532–1540.PubMedCrossRef

15.

Liem, S. S., van der Hoeven, B. L., Oemrawsingh, P. V., Bax, J. J., van der Bom, J. G., Bosch, J., Viergever, E. P., van Rees, C., Padmos, I., Sedney, M. I., van Exel, H. J., Verwey, H. F., Atsma, D. E., van der Velde, E. T., Jukema, J. W., van der Wall, E. E., & Schalij, M. J. (2007). MISSION!: optimization of acute and chronic care for patients with acute myocardial infarction. American Heart Journal, 153, 14–11.PubMedCrossRef

16.

Dominici, M., Le, B. K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D., & Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8, 315–317.PubMedCrossRef

17.

Amado, L. C., Saliaris, A. P., Schuleri, K. H., St, J. M., Xie, J. S., Cattaneo, S., Durand, D. J., Fitton, T., Kuang, J. Q., Stewart, G., Lehrke, S., Baumgartner, W. W., Martin, B. J., Heldman, A. W., & Hare, J. M. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, 102, 11474–11479.PubMedCrossRef

18.

Beitnes, J. O., Oie, E., Shahdadfar, A., Karlsen, T., Muller, R. M., Aakhus, S., Reinholt, F. P., & Brinchmann, J. E. (2012). Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left ventricular function. Cell Transplantation, 21, 1697–1709.CrossRef

19.

Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J., & Kessler, P. D. (2002). Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation, 105, 93–98.PubMedCrossRef

20.

Jain, M., Pfister, O., Hajjar, R. J., & Liao, R. (2005). Mesenchymal stem cells in the infarcted heart. Coronary Artery Disease, 16, 93–97.PubMedCrossRef

21.

Uccelli, A., Moretta, L., & Pistoia, V. (2006). Immunoregulatory function of mesenchymal stem cells. European Journal of Immunology, 36, 2566–2573.PubMedCrossRef

22.

Le Blanc, K., & Ringden, O. (2007). Immunomodulation by mesenchymal stem cells and clinical experience. Journal of Internal Medicine, 262, 509–525.PubMedCrossRef

23.

Huang, X. P., Sun, Z., Miyagi, Y., McDonald, K. H., Zhang, L., Weisel, R. D., & Li, R. K. (2010). Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation, 122, 2419–2429.PubMedCrossRef

24.

Nauta, A. J., Westerhuis, G., Kruisselbrink, A. B., Lurvink, E. G., Willemze, R., & Fibbe, W. E. (2006). Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood, 108, 2114–2120.PubMedCrossRef

25.

Chen, X., Xu, H., Wan, C., McCaigue, M., & Li, G. (2006). Bioreactor expansion of human adult bone marrow-derived mesenchymal stem cells. Stem Cells, 24, 2052–2059.PubMedCrossRef

26.

Meliga, E., Strem, B. M., Duckers, H. J., & Serruys, P. W. (2007). Adipose-derived cells. Cell Transplantation, 16, 963–970.PubMedCrossRef

27.

Planat-Benard, V., Silvestre, J. S., Cousin, B., Andre, M., Nibbelink, M., Tamarat, R., Clergue, M., Manneville, C., Saillan-Barreau, C., Duriez, M., Tedgui, A., Levy, B., Penicaud, L., & Casteilla, L. (2004). Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation, 109, 656–663.PubMedCrossRef

28.

Valina, C., Pinkernell, K., Song, Y. H., Bai, X., Sadat, S., Campeau, R. J., Le Jemtel, T. H., & Alt, E. (2007). Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. European Heart Journal, 28, 2667–2677.PubMedCrossRef

29.

Schenke-Layland, K., Strem, B. M., Jordan, M. C., Deemedio, M. T., Hedrick, M. H., Roos, K. P., Fraser, J. K., & MacLellan, W. R. (2009). Adipose tissue-derived cells improve cardiac function following myocardial infarction. The Journal of Surgical Research, 153, 217–223.PubMedCrossRef

30.

Katritsis, D. G., Sotiropoulou, P. A., Karvouni, E., Karabinos, I., Korovesis, S., Perez, S. A., Voridis, E. M., & Papamichail, M. (2005). Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheterization and Cardiovascular Interventions, 65, 321–329.PubMedCrossRef

31.

Tse, H. F., Thambar, S., Kwong, Y. L., Rowlings, P., Bellamy, G., McCrohon, J., Thomas, P., Bastian, B., Chan, J. K., Lo, G., Ho, C. L., Chan, W. S., Kwong, R. Y., Parker, A., Hauser, T. H., Chan, J., Fong, D. Y., & Lau, C. P. (2007). Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). European Heart Journal, 28, 2998–3005.PubMedCrossRef

32.

Losordo, D. W., Henry, T. D., Davidson, C., Sup, L. J., Costa, M. A., Bass, T., Mendelsohn, F., Fortuin, F. D., Pepine, C. J., Traverse, J. H., Amrani, D., Ewenstein, B. M., Riedel, N., Story, K., Barker, K., Povsic, T. J., Harrington, R. A., & Schatz, R. A. (2011). Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circulation Research, 109, 428–436.PubMedCrossRef

33.

Fuchs, S., Kornowski, R., Weisz, G., Satler, L. F., Smits, P. C., Okubagzi, P., Baffour, R., Aggarwal, A., Weissman, N. J., Cerqueira, M., Waksman, R., Serrruys, P., Battler, A., Moses, J. W., Leon, M. B., & Epstein, S. E. (2006). Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. The American Journal of Cardiology, 97, 823–829.PubMedCrossRef

34.

Tse, H. F., Kwong, Y. L., Chan, J. K., Lo, G., Ho, C. L., & Lau, C. P. (2003). Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet, 361, 47–49.PubMedCrossRef

35.

Ang, K. L., Chin, D., Leyva, F., Foley, P., Kubal, C., Chalil, S., Srinivasan, L., Bernhardt, L., Stevens, S., Shenje, L. T., & Galinanes, M. (2008). Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nature Clinical Practice. Cardiovascular Medicine, 5, 663–670.PubMedCrossRef

36.

Brunskill, S. J., Hyde, C. J., Doree, C. J., Watt, S. M., & Martin-Rendon, E. (2009). Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease. European Journal of Heart Failure, 11, 887–896.PubMedCrossRef

37.

Krause, K., Jaquet, K., Schneider, C., Haupt, S., Lioznov, M. V., Otte, K. M., & Kuck, K. H. (2009). Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study. Heart, 95, 1145–1152.PubMedCrossRef

38.

Antoni, M. L., Hoogslag, G. E., Boden, H., Liem, S. S., Boersma, E., Fox, K., Schalij, M. J., Bax, J. J., & Delgado, V. (2012). Cardiovascular mortality and heart failure risk score for patients after ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention (data from the Leiden MISSION! Infarct Registry). The American Journal of Cardiology, 109, 187–194.PubMedCrossRef

39.

Bellenger, N. G., Burgess, M. I., Ray, S. G., Lahiri, A., Coats, A. J., Cleland, J. G., & Pennell, D. J. (2000). Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? European Heart Journal, 21, 1387–1396.PubMedCrossRef

Title: Intramyocardial Injection of Autologous Bone Marrow-Derived Ex Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients is Feasible and Safe up to 5 Years of Follow-up
Authors: Sander F. Rodrigo
Jan van Ramshorst
Georgette E. Hoogslag
Helèn Boden
Matthijs A. Velders
Suzanne C. Cannegieter
Helene Roelofs
Imad Al Younis
Petra Dibbets-Schneider
Willem E. Fibbe
Jaap Jan Zwaginga
Jeroen J. Bax
Martin J. Schalij
Saskia L. Beeres
Douwe E. Atsma
Publication date: 01-10-2013
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 5/2013
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-013-9507-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intramyocardial Injection of Autologous Bone Marrow-Derived Ex Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients is Feasible and Safe up to 5 Years of Follow-up

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Role of Inflammation and Its Mediators in Acute Ischemic Stroke

Biological Imaging of Atherosclerosis: Moving Beyond Anatomy

Hypertrophy Signaling Pathways in Experimental Chronic Aortic Regurgitation

Coronary Flow Reserve from Mouse to Man—from Mechanistic Understanding to Future Interventions

Computed Fractional Flow Reserve (FFTCT) Derived from Coronary CT Angiography

Myocardial Perfusion Imaging with Cardiac Computed Tomography: State of the Art

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page